Skip to content
Menu

JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $122

Benzinga Newsdesk 2 weeks ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $107 to $122.

JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $107 to $122.

Read at benzinga.com